Efficacy and Safety of Abemaciclib in Combination With Endocrine Therapy for HR+/HER2- Advanced or Metastatic Breast Cancer: A Systematic Review and Meta-Analysis.

Zaheer QureshiAbdur JamilEeshal FatimaFaryal AltafRimsha Siddique

Published in: American journal of clinical oncology (2024)

Abemaciclib, particularly in combination with fulvestrant, emerges as an effective therapeutic option for HR+/HER2- advanced or metastatic breast cancer, improving PFS and OS. The higher toxicity profile warrants cautious use, especially in treatment-naive patients.

Keyphrases

metastatic breast cancer
end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
prognostic factors
hiv infected
replacement therapy
smoking cessation